HABP4

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, HABP4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HABP4 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher HABP4 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated HABP4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LIHC, and PRAD are the cancer types where HABP4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
UCECDFSMedianII,III,IV1.0000.434.01026view →
LIHCDFSMedianAll0.0440.553<.00112view →
PRADDFSMedianAll0.0850.774<.0016view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HABP4–UCEC (DFS)

Kaplan–Meier survival curve for HABP4 mutant vs wild-type samples in UCEC.

Open the UCEC breakdown →

Exploration